DE959898T1 - Laktoferrin varianten und verwendungen davon - Google Patents

Laktoferrin varianten und verwendungen davon

Info

Publication number
DE959898T1
DE959898T1 DE0959898T DE97927932T DE959898T1 DE 959898 T1 DE959898 T1 DE 959898T1 DE 0959898 T DE0959898 T DE 0959898T DE 97927932 T DE97927932 T DE 97927932T DE 959898 T1 DE959898 T1 DE 959898T1
Authority
DE
Germany
Prior art keywords
vector
lactoferrin
eukaryotic cell
lactoferrin variant
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE0959898T
Other languages
German (de)
English (en)
Inventor
Orla Conneely
Pauline P. Ward
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
Original Assignee
Baylor College of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College of Medicine filed Critical Baylor College of Medicine
Publication of DE959898T1 publication Critical patent/DE959898T1/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE0959898T 1996-05-31 1997-06-02 Laktoferrin varianten und verwendungen davon Pending DE959898T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1874796P 1996-05-31 1996-05-31
US08/866,544 US6111081A (en) 1996-05-31 1997-05-30 Lactoferrin variants and uses thereof
PCT/US1997/009531 WO1997045136A1 (en) 1996-05-31 1997-06-02 Lactoferrin variants and uses thereof

Publications (1)

Publication Number Publication Date
DE959898T1 true DE959898T1 (de) 2000-05-04

Family

ID=26691448

Family Applications (1)

Application Number Title Priority Date Filing Date
DE0959898T Pending DE959898T1 (de) 1996-05-31 1997-06-02 Laktoferrin varianten und verwendungen davon

Country Status (12)

Country Link
US (1) US6111081A (enExample)
EP (1) EP0959898A4 (enExample)
JP (1) JP2000511424A (enExample)
KR (1) KR20000016159A (enExample)
AU (1) AU707476B2 (enExample)
CA (1) CA2256453A1 (enExample)
DE (1) DE959898T1 (enExample)
ES (1) ES2140362T1 (enExample)
GR (1) GR990300043T1 (enExample)
IL (1) IL127319A (enExample)
NZ (1) NZ333215A (enExample)
WO (1) WO1997045136A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94183A (en) * 1989-05-05 2003-09-17 Baylor College Medicine cDNA SEQUENCE CODING FOR HUMAN LACTOFERRIN PROTEIN OR PORTION THEREOF AND LACTOFERRIN PROTEIN PRODUCED FROM SAID SEQUENCE
JP2002515893A (ja) * 1997-02-03 2002-05-28 ファーミング インテレクチュアル プロパティ ビーブイ ヒトラクトフェリンおよびその改変体の有用な特性
ATE297755T1 (de) * 1997-04-10 2005-07-15 Agennix Inc Verwendung von lactoferrin in der behandlung von beschwerden, die von allergenen verursacht sind
US6399570B1 (en) 1999-02-05 2002-06-04 Agennix, Inc. Antimicrobial/endotoxin neutralizing polypeptide
JP3668241B2 (ja) * 2001-12-28 2005-07-06 株式会社Ｎｒｌファーマ 脂質代謝改善用組成物
US20030213007A1 (en) * 2002-03-27 2003-11-13 Slattery Charles Wilbur Human milk produced by human mammary tissue implanted in non-human host animals and uses thereof
EP2286827A1 (en) 2002-05-10 2011-02-23 Agennix Incorporated Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
AU2003233583A1 (en) * 2002-05-24 2003-12-12 Agennix Incorporated Oral lactoferrin in the treatment of respiratory disorders
DK2298338T3 (da) * 2002-09-16 2012-09-24 Agennix Inc Lactoferrin-sammensætninger og fremgangsmåder til behandling af hudsår
JP4795021B2 (ja) * 2002-12-06 2011-10-19 エイジェニックス インコーポレイテッド 敗血症治療における経口用ラクトフェリン
US7592306B2 (en) * 2002-12-10 2009-09-22 Agennix, Inc. Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease
WO2004060392A1 (en) * 2002-12-20 2004-07-22 Ventria Bioscience Lactoferrin protein with iron for treating iron deficiency and anemia
AU2004289170B2 (en) * 2003-06-06 2009-12-17 Agennix Incorporated Lactoferrin as an adjuvant in cancer vaccines
US20040259770A1 (en) * 2003-06-19 2004-12-23 Rush University Medical Center Method for determining leukocyte activation
US20050075277A1 (en) * 2003-07-10 2005-04-07 Agennix Incorporated Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects
WO2006047744A2 (en) * 2004-10-26 2006-05-04 Agennix Incorporated Compositions of lactoferrin related peptides and uses thereof
NZ555163A (en) 2007-05-14 2010-05-28 Fonterra Co Operative Group Methods of immune or hematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer, cancer symptoms, or the symptoms of cancer treatments
RU2340674C1 (ru) * 2007-06-01 2008-12-10 Борис Савельевич Народицкий Способ получения рекомбинантного лактоферрина человека
JP5855239B2 (ja) * 2012-04-23 2016-02-09 株式会社Ｎｒｌファーマ ラクトフェリン融合タンパク質及びその製造方法
EP3533870A4 (en) 2016-10-28 2020-04-08 NRL Pharma, Inc. LACTOFERRIN / ALBUMIN FUSION PROTEIN AND PROCESS FOR PRODUCING THE SAME
WO2020096672A1 (en) 2018-11-09 2020-05-14 The Wistar Institute Of Anatomy And Biology Use of lactoferrin for generating myeloid-derived suppressor cells

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5186117A (en) * 1975-01-27 1976-07-28 Tanabe Seiyaku Co Johoseibiryushiseizainoseiho
GB1575343A (en) * 1977-05-10 1980-09-17 Ici Ltd Method for preparing liposome compositions containing biologically active compounds
US4529561A (en) * 1978-03-24 1985-07-16 The Regents Of The University Of California Method for producing liposomes in selected size range
IN150740B (enExample) * 1978-11-24 1982-12-04 Hoffmann La Roche
GB2046092B (en) * 1979-03-05 1983-11-02 Toyama Chemical Co Ltd Pharmaceutical composition containing a lysophospholid and a phospholipid
US4634665A (en) * 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4394443A (en) * 1980-12-18 1983-07-19 Yale University Method for cloning genes
US4452747A (en) * 1982-03-22 1984-06-05 Klaus Gersonde Method of and arrangement for producing lipid vesicles
US4766075A (en) * 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4652639A (en) * 1982-05-06 1987-03-24 Amgen Manufacture and expression of structural genes
US4725442A (en) * 1983-06-17 1988-02-16 Haynes Duncan H Microdroplets of water-insoluble drugs and injectable formulations containing same
US4703008A (en) * 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
US4740461A (en) * 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4710465A (en) * 1984-04-19 1987-12-01 Yale University Junction-fragment DNA probes and probe clusters
US5008050A (en) * 1984-06-20 1991-04-16 The Liposome Company, Inc. Extrusion technique for producing unilamellar vesicles
LU85479A1 (fr) * 1984-07-25 1986-02-12 Oleofina Sa Compositions antibacteriennes de nourriture pour animaux et procede pour les preparer
US4921706A (en) * 1984-11-20 1990-05-01 Massachusetts Institute Of Technology Unilamellar lipid vesicles and method for their formation
JPS61145200A (ja) * 1984-12-19 1986-07-02 Snow Brand Milk Prod Co Ltd ウシラクトフェリンの分離精製法
US4886747A (en) * 1985-03-22 1989-12-12 Genentech, Inc. Nucleic acid encoding TGF-β and its uses
AU5912586A (en) * 1985-06-20 1986-12-24 Salk Institute Biotechnology/Industrial Associates, Inc., The Alpha-factor leader peptide-facilitated secretion from transformed s cerevisiae
FR2583676B1 (fr) * 1985-06-24 1988-03-25 Induplast Sa Procede et appareils d'extrusion de structures alveolaires en matiere thermoplastique et structures ainsi obtenues
US4959318A (en) * 1985-06-27 1990-09-25 Zymogenetics, Inc. Expression of protein C
US4800159A (en) * 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4737323A (en) * 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4965190A (en) * 1986-07-31 1990-10-23 Howard Hughes Medical Institute Methods for the identification of mutations in the human phenylalanine hydroxylase gene using DNA probes
US4920016A (en) * 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
US5009956A (en) * 1987-02-24 1991-04-23 Univ Minnesota Phospholipase A2-resistant liposomes
US5019508A (en) * 1987-08-27 1991-05-28 Biotechnology Research Partners, Ltd. Synovial phospholipases
DE3886221T3 (de) * 1987-09-04 2000-12-21 Novo Nordisk A/S, Bagsvaerd VERFAHREN ZUR HERSTELLUNG VON PROTEINPRODUKTEN IN -i(ASPERGILLUS) UND PROMOTOREN ZUR VERWENDUNG IN -i(ASPERGILLUS).
US5081227A (en) * 1988-03-04 1992-01-14 La Jolla Cancer Research Foundation Germ cell alkaline phosphatase
US4927637A (en) * 1989-01-17 1990-05-22 Liposome Technology, Inc. Liposome extrusion method
US4944948A (en) * 1989-02-24 1990-07-31 Liposome Technology, Inc. EGF/Liposome gel composition and method
US5571691A (en) * 1989-05-05 1996-11-05 Baylor College Of Medicine Production of recombinant lactoferrin and lactoferrin polypeptides using CDNA sequences in various organisms
US5571697A (en) * 1989-05-05 1996-11-05 Baylor College Of Medicine Texas Medical Center Expression of processed recombinant lactoferrin and lactoferrin polypeptide fragments from a fusion product in Aspergillus
US5155037A (en) * 1989-08-04 1992-10-13 The Texas A&M University System Insect signal sequences useful to improve the efficiency of processing and secretion of foreign genes in insect systems
IL95697A0 (en) * 1989-09-28 1991-06-30 Granada Biosciences Inc Cdna sequence for porcine lactoferrin protein
AU7453391A (en) * 1990-03-08 1991-10-10 Ferrodynamics, Inc. Genetically engineered human lactoferrin
JP2818056B2 (ja) * 1990-09-07 1998-10-30 森永乳業株式会社 抗菌性ペプチドおよび抗菌剤
US5166145A (en) * 1990-09-10 1992-11-24 Alza Corporation Antiemetic therapy
NZ245713A (en) * 1992-02-10 1994-12-22 Novopharm Ltd Production of the antibiotic lovastatin from genetically engineered aspergillus strains
ZA932568B (en) * 1992-04-24 1993-11-12 Baylor College Midecine A Non Production of recombinant human lactoferrin
US5571619A (en) * 1994-05-24 1996-11-05 Exxon Chemical Patents, Inc. Fibers and oriented films of polypropylene higher α-olefin copolymers

Also Published As

Publication number Publication date
AU3227197A (en) 1998-01-05
US6111081A (en) 2000-08-29
NZ333215A (en) 2000-05-26
JP2000511424A (ja) 2000-09-05
KR20000016159A (ko) 2000-03-25
GR990300043T1 (en) 2000-01-31
ES2140362T1 (es) 2000-03-01
CA2256453A1 (en) 1997-12-04
EP0959898A4 (en) 2002-08-14
WO1997045136A1 (en) 1997-12-04
AU707476B2 (en) 1999-07-08
EP0959898A1 (en) 1999-12-01
IL127319A0 (en) 1999-09-22
IL127319A (en) 2004-08-31

Similar Documents

Publication Publication Date Title
DE68908491T2 (de) Insulinvorläufer, deren Herstellung und DNA-Sequenzen, Expressionsvehikel und Primer und ein Prozess zur Herstellung von Humaninsulin und Analoge.
DE3586773T2 (de) Verfahren zur beseitigung von n-endaminosaeureresten aus eukaryotpolypeptidanlagen und so erzeugte polypeptide.
DE3650101T2 (de) Analoga von Insulin und deren Herstellungsmethode.
CA2019363A1 (en) Dna and use thereof
DE68927583T2 (de) Für menschliches Serum Albumin (HSA) kodierende DNA, Plasmide und Wirtzellen, die solche DNA enthalten sowie die Herstellung von HSA
DE93619T1 (de) Plasminogenaktivator fuer menschliches gewebe, diesen aktivator enthaltende pharmazeutische zusammensetzungen, verfahren zur herstellung des aktivators sowie dna und transformierte zellzwischenprodukte hierfuer.
DE69535704T2 (de) EXPRESSIONSPLASMIDE, DURCH EINEN osmB PROMOTER REGULIERT
DE278776T1 (de) Verfahren und Desoxyribonukleinsäure zur Herstellung von Gewebefaktor-Protein.
ATE196507T1 (de) Verfahren zur herstellung von viralen vektoren von mindestens 20kb durch intermolekulare homologe rekombination in einer prokaryotischen zelle
DE20251T1 (de) Dns-transfer-vektor, damit transformierter wirt, impfstoff und ihre herstellung.
DE951551T1 (de) Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie
DE69228497D1 (de) Expression von menschlichen Serum-Albuminen in Pichia Pastoris
DE137280T1 (de) Rekombinante cellobiohydrolasen aus pilzen.
DE2817866A1 (de) Polypeptide fuer kosmetische praeparate
WO1990010067A1 (de) Pth-varianten kodierende dna-sequenzen, pth-varianten, expressionsvektor, bakterieller wirt, verwendung und therapeutische zusammensetzung
DE146944T1 (de) Menschliches gamma-interferonpolypeptidderivat.
NZ333215A (en) a nucleic acid sequence encoding a lactoferrin variant or portion thereof which has modified iron binding capacity
DE3854879T2 (de) Rekombinantes Enzym zur alpha-Amidierung von C-Termini
DE932679T1 (de) Verfahren und zusammensetzungen zur verabreichung und expression von interferon-alpha nukleinsäuren
DE237398T1 (de) Verfahren zur herstellung biologisch aktiver polypeptide, so erhaltene polypeptide und diese enthaltende zusammensetzungen.
DE152483T1 (de) Verfahren zur herstellung von peptiden.
Bell et al. Sequence of a cDNA encoding guinea pig IGF-I
DE69124561T2 (de) Methode zur reinigung von polypeptiden
GR3026465T3 (en) Biosynthetic process for the preparation of proteins.
AU1090688A (en) Synthetic porcine growth hormone